The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial

Journal of the American College of Cardiology

Volumn 67, Issue 24, 2016, Pages 2846-2854

  Tsuyuki, Ross T ^a,b   Al Hamarneh, Yazid N ^a,b   Jones, Charlotte A ^c   Hemmelgarn, Brenda R ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

blood pressure; diabetes; dyslipidemia; smoking

Indexed keywords

HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ALBERTA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE FINDING; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MULTICENTER STUDY (TOPIC); PATIENT EDUCATION; PHARMACIST; PHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIAS; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

ALBERTA; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COMMUNITY PHARMACY SERVICES; CONTINUITY OF PATIENT CARE; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MALE; MEDICATION RECONCILIATION; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; RISK ASSESSMENT; SMOKING; SMOKING CESSATION;

EID: 84979626564     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.528     Document Type: Article

References (37)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
2. 2 Statistics Canada. Causes of Death, Canada, 2011. CANSIM (Canadian Socio-Economic Information Management System) data. January 28, 2014; catalog number 82-625-X.
3. 3 National Center for Health Statistics. Health, United States, 2014: With Special Feature on Adults Aged 55–64. Hyattsville, MD: 2015.
4. 4 Centers for Disease Control and Prevention (CDC). Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors–United States, 2011. MMWR Morb Mortal Wkly Rep 60 (2011), 1248–1251.
5. 5 Lim, S.S., Vos, T., Flaxman, A.D., et al. A comparative assessment of burden of disease injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 380 (2012), 2224–2260.
6. 6 Mosca, L., Barrett-Connor, E., Wenger, N.K., Sex/Gender differences in cardiovascular disease prevention what a difference a decade makes. Circulation 124 (2011), 2145–2154.
7. 7 Braga, M., Casanova, A., Teoh, H., et al. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol 26 (2010), 297–302.
8. 8 Al Hamarneh, Y.N., Rosenthal, M., Tsuyuki, R.T., Glycemic control in community dwelling patients with type 2 diabetes. Can Pharm J 145 (2012), 68–69.e1.
9. 9 Ritchey, M.D., Wall, H.K., Gillespie, C., George, M.G., Jamal, A., Million hearts: prevalence of leading cardiovascular disease risk factors–United States, 2005-2012. MMWR Morb Mortal Wkly Rep 63 (2014), 462–467.
10. 10 Leiter, L.A., Berard, L., Bowering, C.K., et al. Type 2 diabetes mellitus management in Canada: is it improving?. Can J Diabetes 37 (2013), 82–89.
11. 11 Grover, S.A., Lowensteyn, I., The challenges and benefits of cardiovascular risk assessment in clinical practice. Can J Cardiol 27 (2011), 481–487.
12. 12 Shiu, J.R., Simpson, S.H., Johnson, J.A., Tsuyuki, R.T., Quantifying opportunities to affect diabetes management in the community. Can Pharm J 139 (2006), 37–38.
13. 13 Vivian, E.M., Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy 21 (2001), 1337–1344.
14. 14 Scott, D.M., Boyd, S.T., Stephan, M., et al. Outcomes of pharmacist-managed diabetes care services in a community health centre. Am J Health-Syst Pharm 63 (2006), 2116–2122.
15. 15 Santschi, V., Chiolero, A., Burnand, B., Colosimo, A.L., Paradis, G., Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 171 (2011), 1441–1453.
16. 16 Tsuyuki, R.T., Johnson, J.A., Teo, K.K., et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management – the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 162 (2002), 1149–1155.
17. 17 McLean, D.L., McAlister, F.A., Johnson, J.A., et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus – Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Arch Intern Med 168 (2008), 2355–2361.
18. 18 Okonofua, E.C., Simpson, K.N., Jesri, A., et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 47 (2006), 345–351.
19. 19 Kassamali, A., Houle, S., Rosenthal, M., Tsuyuki, R.T., Case finding: the missing link in chronic disease management. Can Pharm J 144 (2011), 170–171.e1.
20. 20 Daskalopoulou, S.S., Rabi, D.M., Zarnke, K., for the Canadian Hypertension Education Program. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 31 (2015), 549–568.
21. 21 Stevens, R.J., Kothari, V., Adler, A.I., Stratton, I.M., Holman, R.R., The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 101 (2001), 671–679.
22. 22 Wilson, P.W.F., D'Agostino, R., Bhatt, D.L., et al. An international model to predict recurrent cardiovascular disease. Am J Med 125 (2012), 695–703.
23. 23 D'Agostino, R.B., Vasan, R.S., Pencina, M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117 (2008), 743–753.
24. 24 Grover, S.A., Lowensteyn, I., Joseph, L., et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy. The CHECK-UP Study: a randomized controlled trial. Arch Intern Med 167 (2007), 2296–2303.
25. 25 International Society of Nephrology. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
26. 26 Canadian Diabetes Association. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 37 (2013), S1–S212.
27. 27 Hackam, D., Quinn, R., Ravani, P., et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 29 (2013), 528–542.
28. 28 Genest, J., McPherson, R., Frohlich, J., et al. 2009 Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations. Can J Cardiol 25 (2009), 567–579.
29. 29 Anderson, T.J., Grégoire, J., Hegele, R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29 (2013), 151–167.
30. 30 Tobe, S., Stone, J., Brouwers, M., et al. Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE initiative. CMAJ 183 (2011), E1135–E1150.
31. 31 Al Hamarneh, Y.N., Charrois, T., Lewanczuk, R., et al. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open, 3, 2013 e003154.
32. 32 Tsuyuki, R.T., Houle, S.K., Charrois, T.L., et al. Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). Circulation 132 (2015), 93–100.
33. 33 O'Donovan, D.O., Byrne, S., Sahm, L.J., Pharmacist's use of screening tools to estimate risk of CVD: a review of the literature. Pharmacy 2 (2014), 27–39.
34. 34 McNamara, K.P., George, J., O'Reilly, S.L., et al. Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the pharmacist assessment of adherence, risk and treatment of cardiovascular disease (PAART CVD) pilot study. BMC Health Serv Res 10 (2010), 264–271.
35. 35 McNamara K, Bunker S, Dunbar J, et al. Pharmacist assessment and adherence, risk and treatment of cardiovascular disease (PAART CVD). 2015. Available at: http://guild.org.au/services-programs/research-and-development/archive–fourth-agreement/iig-015. Accessed February 28, 2016.
36. 36 Al Hamarneh, Y.N., Hemmelgarn, B., Curtis, C., et al. Community pharmacists targeted screening for chronic kidney disease. Can Pharm J 149 (2016), 13–17.
37. 37 Curtis, C., Balint, C., Al Hamarneh, Y.N., et al. Online clinical pathway for managing adults with chronic kidney disease. Can Pharm J 148 (2015), 257–262.